SKIM names Maura Coracini as Managing Director, Latin America
SKIM has named Maura Coracini as Managing Director, Latin America. Based in the São Paulo area.
Of all recent developments in the pharmaceutical industry, only few have provoked such controversy and commotion as biosimilars. Especially the recent breakthrough entry of biosimilar monoclonal antibodies have brought a new level of complexity, making it a much tougher environment for biologics originators. It’s no longer just about lowering costs.
To help you stay competitive against biosimilars challenges, we shared with you our key strategies to overcome these challenges during the Pharma Market Research Conference (PMRC) Europe 2017.
Presenter: Adriënne Hoevers – den Hollander, Senior Research Manager
Biosimilars: How to stay competitive against a pending new wave of entrants
At SKIM we have learned from studies over the past few years, that not only lower costs but also many complex factors need to be considered in order to determine future impact of biosimilars. Understanding how these factors will influence uptake and how this may evolve over time will be essential for originator companies to build effective strategies across therapy areas, settings, and countries.
In this presentation we shared our views on how market research and analytics can help forecast and impact the uptake of biosimilars in different market situations. We put these views into practice by sharing learnings and challenges from a recent uptake study in the area of rheumatology among physicians and pharmacists.
